Hidayati, Hanik Badriyah and Octavia, Evi and Srisetyaningrum, Cempaka Thursina (2021) Antiviral therapy for COVID-2019. Anaesthesia, Pain and Intensive Care, 25 (3). 387 – 392. ISSN 16078322
Full text not available from this repository. (Request a copy)Abstract
The whole world is experiencing a global pandemic caused by Coronavirus disease 2019. As the pandemic progresses, there has been much research on antiviral drugs, such as hydroxychloroquin, chloroquine, remdesivir, lopinavir-ritonavir, favipiravir, oseltamivir, and umifenovir. Specific antiviral drugs proven to be effective against SARS-CoV-2 have not been found and approved for the medication of COVID-19. Currently, case detection, infection control, monitoring, prevention, and supportive care are the means focused on the treatment of COVID-19. A large scale research is currently underway to analyze safety and efficacy of antiviral drugs, while trials of the SAR-CoV-2 vaccine are rapidly expanding. This mini review briefly introduces the current antiviral therapy for COVID-19. © 2021 Faculty of Anaesthesia, Pain and Intensive Care, AFMS. All rights reserved.
| Item Type: | Article |
|---|---|
| Additional Information: | Cited by: 1 |
| Uncontrolled Keywords: | antivirus agent; chloroquine; favipiravir; hydroxychloroquine; lopinavir plus ritonavir; oseltamivir; remdesivir; umifenovir; antiviral therapy; coronavirus disease 2019; human; infection control; nonhuman; pandemic; Review; Severe acute respiratory syndrome coronavirus 2 |
| Subjects: | R Medicine > RB Biomedical Sciences |
| Divisions: | Faculty of Medicine, Public Health and Nursing > Biomedical Sciences |
| Depositing User: | Sri JUNANDI |
| Date Deposited: | 26 Sep 2024 01:02 |
| Last Modified: | 26 Sep 2024 01:02 |
| URI: | https://ir.lib.ugm.ac.id/id/eprint/4647 |
Actions (login required)
- View Item